SOBRE ESTE EPISÓDIO
Lumos Diagnostics Chief Commercial Officer Paul Kase joined Steve Darling from Proactive to discuss the expansion of the company's FebriDx rapid diagnostic test across an additional 97 WellStreet Urgent Care locations, bringing the total number of participating clinics in the network to 141.
FebriDx is a rapid point-of-care diagnostic test that uses a fingerstick blood sample to help healthcare professionals distinguish between bacterial and non-bacterial infections. The test is designed to support clinical decision-making, particularly when assessing patients with respiratory infections.
Lumos began its relationship with WellStreet through a single-site pilot agreement in Atlanta, Georgia, in October 2025. WellStreet is one of the largest urgent care networks in the United States, operating more than 200 clinics and managing over 1 million acute respiratory infection presentations annually.
Kase told Proactive that the expanded rollout is expected to increase the total number of US sites using FebriDx to 365 once implementation is complete. The expansion represents a significant step in Lumos' commercial growth strategy, increasing the test's reach in one of the world's largest point-of-care diagnostics markets.
The broader deployment also provides further commercial validation for FebriDx, while giving Lumos access to a substantial volume of respiratory infection presentations through WellStreet's established clinic network.
Lumos and WellStreet anticipate extending FebriDx testing across all of WellStreet's more than 200 locations and markets by December 31, 2026. The wider rollout would put the test within reach of a healthcare network handling more than 1 million acute respiratory presentations each year.
Lumos will continue to support implementation across the additional clinics as WellStreet integrates FebriDx into its standardized triage protocols.
#proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #FebriDx #WellStreetUrgentCare #Diagnostics #RapidTesting #PointOfCare #Healthcare #MedTech #InfectiousDisease #RespiratoryInfections
FebriDx is a rapid point-of-care diagnostic test that uses a fingerstick blood sample to help healthcare professionals distinguish between bacterial and non-bacterial infections. The test is designed to support clinical decision-making, particularly when assessing patients with respiratory infections.
Lumos began its relationship with WellStreet through a single-site pilot agreement in Atlanta, Georgia, in October 2025. WellStreet is one of the largest urgent care networks in the United States, operating more than 200 clinics and managing over 1 million acute respiratory infection presentations annually.
Kase told Proactive that the expanded rollout is expected to increase the total number of US sites using FebriDx to 365 once implementation is complete. The expansion represents a significant step in Lumos' commercial growth strategy, increasing the test's reach in one of the world's largest point-of-care diagnostics markets.
The broader deployment also provides further commercial validation for FebriDx, while giving Lumos access to a substantial volume of respiratory infection presentations through WellStreet's established clinic network.
Lumos and WellStreet anticipate extending FebriDx testing across all of WellStreet's more than 200 locations and markets by December 31, 2026. The wider rollout would put the test within reach of a healthcare network handling more than 1 million acute respiratory presentations each year.
Lumos will continue to support implementation across the additional clinics as WellStreet integrates FebriDx into its standardized triage protocols.
#proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #FebriDx #WellStreetUrgentCare #Diagnostics #RapidTesting #PointOfCare #Healthcare #MedTech #InfectiousDisease #RespiratoryInfections
Inglês
Estados Unidos da América
TRANSCRIÇÃO 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
PESQUISAR EPISÓDIOS PASSADOS
Pesquisar episódios anteriores de Proactive - Interviews for investors.
OUTROS EPISÓDIOS NESTE PODCAST
FireFly Metals Ltd managing director Steve Parsons talked with Proactive about the latest high-grade drilling results from the company’s Green Bay Copper-Gold Project in Newfoundland, Canada, and how continued resource growth could feed into the upcoming feasibility study.
FireFly Metals is contin…
Sunda Energy PLC (AIM:SNDA, FRA:GHA0) CEO Andy Butler spoke with Proactive's Stephen Gunnion about its planned New Zealand acquisition, production growth opportunities and progress in Timor-Leste.
The New Zealand business produces more than 1,000 barrels of oil per day from the Cheal fields, provi…
Lightning Minerals Ltd managing director Troy Brice talked with Proactive about the completion of Phase 2 diamond drilling at the company’s Mt Turner Gold Project in North Queensland and the pathway toward a maiden gold Mineral Resource Estimate in 2027.
Brice said the drilling team had completed …
Blackbird PLC (AIM:BIRD) CEO Sumit Rai talked with Proactive's Stephen Gunnion about his appointment, the company's next phase of growth and plans to expand its cloud-based video editing platform, elevate.io.
Rai, who has led elevate.io's development since joining Blackbird in 2022, said the busin…
Aviso: O podcast e a arte incorporada nesta página são de Proactive, que é propriedade de seu proprietário e não é afiliado ou endossado por Listen Notes, Inc.
EDITAR
Obrigado por ajudar a manter a base de dados dos podcasts atualizada.
